News | Image Guided Radiation Therapy (IGRT) | October 05, 2018

ViewRay and Miami Cancer Institute Host Symposium on MR-Guided Radiation Therapy

ViewRay MRIdian Linac system helps prolong survival and reduce complications

ViewRay and Miami Cancer Institute Host Symposium on MR-Guided Radiation Therapy

October 5, 2018 — Leading oncology experts from around the world recently met to discuss the integration of magnetic resonance imaging (MRI) with radiation therapy and its potential to extend life expectancy and reduce common side effects in many cancer patients. ViewRay Inc. — maker of MRIdian, the world's first U.S. Food and Drug Administration (FDA)-cleared, MRI-guided radiation therapy system — and Miami Cancer Institute, co-hosted experts from research hospitals at the cutting-edge of cancer treatment at the Sept. 28 symposium and panel discussion.

Presenters and panel participants included:

  • Minesh Mehta, M.D., chief of radiation oncology, and Michael Chuong, M.D., director of radiation oncology clinical research and education, at Miami Cancer Institute, a part of Baptist Health South Florida;
  • Michael Bassetti, M.D., Ph.D., assistant professor of radiation oncology at University of Wisconsin, Carbone Cancer Center; and
  • Raymond Wynn, M.D., FACR, professor and vice chair of network operations in the department of radiation oncology at Loyola University Medical Center.

"Seldom do we see this much excitement around a technology," Mehta said. "For the first time, we're able to see high-contrast soft tissue images that clearly delineate tumors from the surrounding healthy organs. This allows us to deliver radiation more precisely, and in some cases, may even allow us to increase the radiation dose to more aggressively fight the cancer."

"MRIdian has taken much of the guesswork out of radiation therapy. Its visualization and adaptive abilities are of benefit in treating many types of cancer, but they are especially vital when treating tumors that move significantly during treatment, such as tumors in the lung or liver. We can now watch the changes within the body in real-time and respond accordingly," Chuong said. "This leads to more accurate treatment of the tumor and minimizes irradiation of nearby normal tissues, potentially reducing the side effects."

"This technology is a true game-changer, and we are honored to be the first center in Illinois and first community practice nationwide to offer it to our patients," Wynn said. "MRI-guided radiation therapy enables us to deliver more accurate and effective radiation doses, in fewer sessions, while sparing healthy tissue. This now makes what was science fiction a science reality."

"Seeing the tumor and surrounding healthy tissues and organs in great detail allows us to adapt the treatment in order to improve dosing and accuracy," Bassetti said. "Early results in pancreatic cancer suggest that the ability to deliver higher radiation doses with adaptive MRI-guided radiation therapy may improve patient survival while maintaining low toxicity. We look forward to further investigating these promising outcomes."

ViewRay has announced the launch of a multi-center prospective clinical trial in pancreatic cancer to investigate the robustness of encouraging early data in patients treated with MRI-guided radiation therapy. The study aims to track patient survival and quality of life over a five-year period. The trial is expected to open enrollment in the coming weeks.

Watch the VIDEO: MRI-Guided Radiation Therapy Trial for Pancreatic Cancer, an interview with Benjamin Movsas, M.D., and Carrie Glide-Hurst, Ph.D., of Henry Ford Hospital System, about the ViewRay pancreatic cancer trial.

For more information: www.viewray.com

 

Related Content

the Contrast Media Injectors Market is estimated to be USD 1.3 billion in 2020 and  projected to reach $1.9B by 2025, at a CAGR of 7.4% between 2020 and 2025

Getty Images

News | Contrast Media Injectors | September 02, 2020
September 2, 2020 — According to the new market research report "...
The global pediatric imaging market size is expected to reach $12.2 billion by 2027, registering a CAGR of 7.6% over the forecast period, according to a new report by Grand View Research, Inc.

Getty Images

News | Pediatric Imaging | August 26, 2020
August 26, 2020 — The global ...
Single-dose radiotherapy replaces need for extra hospital visits, with benefits for patient safety and well-being

Getty Images

News | Women's Health | August 20, 2020
August 20, 2020— For most women with early breast cancer
AI-Rad Companion Prostate MR for Biopsy Support segments prostate for targeted biopsy under MRI and ultrasound fusion imaging

Image courtesy of Clinica Universidad de Navarra, Spain

News | Artificial Intelligence | August 19, 2020
August 19, 2020 — The Food and Drug Administration (FDA) has cleared two additional...
The first and only FDA-approved gadolinium-based contrast agent for multi-patient dosing with an FDA-cleared Transfer Spike in the MR suite
News | Contrast Media | August 14, 2020
August 14, 2020 — The U.S.
Videos | Cardiac Imaging | August 12, 2020
Advanced visualization company...
Rafael Rivero, M.D., Global Head of Medical Affairs at MSI, said: "The importance of MyoStrain cannot be understated because of the test's immense clinical value and ability to quantify intramyocardial dysfunction across 48 segments of the heart. In a six-heartbeat MRI scan, MyoStrain arms physicians with novel clinical information about a patient's heart health."
News | Cardiac Imaging | August 11, 2020
August 11, 2020 — Myocardial Solutions, Inc. and United Imaging, Inc.